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Abstract

Funding information

methods used missed the molecular cause in a known gene, or a novel causative

H2020 Health, Grant/Award Numbers:
European Joint Programme on Rare Diseases
(EJP‐RD), SolveRD / 779257; FP7 Health,
Grant/Award Numbers: RD‐Connect, an
integrated platform connecting registries,
biobanks and clinical bioinformatics

gene could not be identified and/or confirmed. To address these challenges, the RD‐

Rare disease patients are more likely to receive a rapid molecular diagnosis
nowadays thanks to the wide adoption of next‐generation sequencing. However,
many cases remain undiagnosed even after exome or genome analysis, because the

Connect Genome‐Phenome Analysis Platform (GPAP) facilitates the collation,
discovery, sharing, and analysis of standardized genome‐phenome data within a
collaborative environment. Authorized clinicians and researchers submit pseudonymised phenotypic profiles encoded using the Human Phenotype Ontology, and raw
genomic data which is processed through a standardized pipeline. After an optional
embargo period, the data are shared with other platform users, with the objective
that similar cases in the system and queries from peers may help diagnose the case.
Additionally, the platform enables bidirectional discovery of similar cases in other
databases from the Matchmaker Exchange network. To facilitate genome‐phenome
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analysis and interpretation by clinical researchers, the RD‐Connect GPAP provides a
powerful user‐friendly interface and leverages tens of information sources. As a
result, the resource has already helped diagnose hundreds of rare disease patients
and discover new disease causing genes.
KEYWORDS

data sharing, data standardization, diagnostics, genome analysis, NGS, patient matchmaking,
rare diseases

1

| INTRODUCTION

methodology improves over time, it is beneficial to keep the
phenotypic and genomic data properly organized to facilitate review

Recent estimates suggest that between 3.5% and 7% of the world's

of the data with manual or semi‐automated procedures on a regular

population is affected by a rare disease (RD) at some point in their

basis. However, historically this task has been made difficult by the

lifetime, placing significant social, emotional, and economic burden

lack of widely adopted standardized formats and nomenclature for

on society (Nguengang Wakap et al., 2020; https://ec.europa.eu/

describing genomic and phenotypic data.

the

Furthermore, as many RDs are extremely rare, having an

last decade the advent of cost‐effective massively parallel shotgun

incidence of less than 1 per million (Nguengang Wakap et al.,

DNA sequencing, often referred to as next generation sequencing,

2020), the means to locate other patients with similar phenotypes

has been a major boon to the study of rare Mendelian diseases. The

can greatly aid in reaching a diagnosis. Therefore, one way in which

wide‐scale application of exome sequencing, and more recently

the pace of research can be accelerated, and hence the time to

genome sequencing, to large numbers of cases with similar

diagnosis for RD patients be reduced, is through the promotion of the

phenotypes has allowed researchers to identify many novel disease

sharing of standardized phenotypic descriptions and genomic data in

genes and variants, and provide molecular diagnoses to thousands

line with FAIR (Findable, Accessible, Interoperable, Reusable) princi-

health/non_communicable_diseases/rare_diseases_en). Over

of affected individuals (e.g., Fitzgerald et al., 2015; Retterer et al.,

ples (Wilkinson et al., 2016). However, the sharing of RD patient data

2016; Stranneheim et al., 2021; Turnbull et al., 2018; Wright,

faces a number of barriers as outlined in Box 1.

McRae, et al., 2018).

In recent years, there has been much effort within the RD

Nevertheless, even in specialist clinics, the majority of RDs will

community towards overcoming these barriers, in particular with

only be encountered once, if ever, by primary care physicians, and the

respect to the standardization of methodology and terminology for

heterogeneous, and sometimes dynamic, nature of symptoms with

recording phenotypic descriptions, and the responsible processing

which many RD patients present means that correct diagnosis of the

and sharing of genomic data. These ongoing efforts include initiatives

underlying disease poses a significant challenge. Unfortunately, this

such as the human phenotype ontology (HPO, Köhler et al., 2021),

often leads to patients and their families undergoing a diagnostic

the orphanet rare disease ontology (ORDO, Nguengang Wakap et al.,

odyssey whereby they receive a number of possible diagnoses over

2020), ClinVar (Landrum et al., 2020), the American College of

the course of several years, before a definitive diagnosis is eventually

Medical Genetics (ACMG) standards for variant interpretation

reached. This can result in delayed and/or missed opportunities for

(Richards et al., 2015), Matchmaker Exchange (MME, Philippakis

counseling, prevention, and treatment (Boycott et al., 2017).

et al., 2015; Boycott et al., 2022), Genomics England PanelApp

There are a variety of bottlenecks that impede rapid resolution of

(Martin et al., 2019), and work along many different lines within the

RD cases through the application of next generation sequencing. One

Global Alliance for Genomics and Health (GA4GH). All these efforts,

is the collection of the data itself, which is time consuming and

and many others, will hopefully enable “all people living with a RD to

requires the work of many skilled individuals, from the medical

receive an accurate diagnosis, care, and available therapy within one

practitioners who examine the patient, record their phenotype and

year of coming to medical attention,” which is the ambitious vision of

extract samples, to the specialized laboratory staff who perform DNA

the International Rare Disease Research Consortium (IRDiRC) for

sequencing, and the bioinformaticians who process the data to

2027 (Austin et al., 2018).

identify variants, supported by high performance computing infra-

The primary goal of the European Union FP7 funded RD‐

structures. The ensuing challenge is to identify the one or two

Connect project was to accelerate RD research by connecting

disease‐causing variants out of the millions found in each human

databases, patient registries, biobanks, and clinical bioinformatics

genome. This requires the blending of information from many

data through an intuitive user‐friendly platform to simplify the

different data sources to aid variant interpretation, ideally using

analysis of RD cases within a collaborative framework (Lochmüller

user‐friendly systems that can efficiently help clinical researchers

et al., 2018; Thompson et al., 2014). One of the key assets developed

achieve this goal. As scientific knowledge constantly grows and

in this project to overcome many of the barriers highlighted in
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Barriers to sharing Rare Disease data

RD data often remains effectively siloed, thus impeding research and diagnoses, for a number of reasons, which may differ for different
groups of stakeholders (e.g., funders, clinicians, researchers, industry, etc.).

1) Motivational
A. Culture of protecting research data to reduce the chance of prior publication by competing peers.
B. Concerns about intellectual property that could be derived from the data by third parties.
C. Cost of making and maintaining the data interoperable, discoverable, and accessible.
D. Lack of incentives for sharing data.
E. Concerns regarding quality of one's own data.
2) Logistical
A. Data may not be findable. Clinical researchers often do not know which other professionals have similar cases.
B. Clinicians lack the time and resources to fully describe their own cases in a standardized format which would facilitate sharing
and automated analysis.
C. Language barriers ‐ RD case descriptions may be written in different languages, and thus time consuming and difficult to
compare.
D. Relevant information may have to be compiled from different sources (e.g. electronic health records, project databases, local
files, etc.) requiring time consuming effort.
3) Technical
A. Data may not be discoverable and/or accessible. Relevant data is often stored across different servers/databases which are not
freely accessible outwith the institution to which they belong.
B. Processes to request access to data may not be clear, or too cumbersome.
C. Data may not be interoperable. Where common standards are not widely implemented, even in cases where communication is
permitted, data is often stored in incompatible formats which are not machine readable, e.g. free‐form patient descriptions in
electronic health records.
D. Sequencing data is large in size, of the order of 10–100 Gigabytes of raw data per individual. Thus it requires highly specialized
knowledge, tools, and computing resources to manage, process, analyze, interpret, store, and distribute.
4) Ethical and Legal
A. Data may not be reusable for example, if there is not an appropriate legal basis for processing in place, such as informed
consent, permitting such usage.
B. Patient data is inherently private, and thus sharing must be limited, and in line with national and international legal restrictions
for example, the European General Data Protection Regulation (GDPR), to prevent undesired re‐identification.

Box 1 was the RD‐Connect Genome‐Phenome Analysis Platform

project/id/951724), ELIXIR (https://elixir‐europe.org/), Matchmaker

(RD‐Connect GPAP), which is now an IRDiRC recognized resource

Exchange (MME), and the Global Alliance for Genomics and Health

(Lochmüller et al., 2017). It was designed from the ground up with

(GA4GH).

leadership from RD clinicians involved in diagnosis and gene

Here, we describe in detail the RD‐Connect GPAP, a scalable and

discovery in their own patient cohorts, giving it a unique perspective

interoperable online system which facilitates the collation, analysis,

focused on the bottlenecks they face in their own research and

interpretation, and sharing of integrated genome‐phenome datasets,

diagnostic practice. The platform is free to use for RD researchers

with a particular focus on RD case diagnosis and novel gene

and clinicians who have the appropriate legal basis, such as informed

discovery. We provide an overview of the different modules that

consent, to share their participants’ (affected individuals and

comprise the RD‐Connect GPAP, and detail how it facilitates filtering

relatives) genomic and phenotypic data with other registered users.

and prioritization of variants based upon both the phenotypic

The RD‐Connect GPAP has been used as the primary analysis tool in

information provided and the incorporation of a wide variety of

a number of large European projects and is involved in many ongoing

openly accessible annotations and tools. Further, we describe how

projects and initiatives including Solve‐RD (https://cordis.europa.eu/

case data can be shared in a controlled manner to support internal

project/id/779257), the European Joint Program on Rare Diseases

and external patient matchmaking, and how case resolution is

(EJP‐RD, https://cordis.europa.eu/project/id/951724), the Beyond

recorded within the platform, in line with the ACMG guidelines.

One Million Genomes project (B1MG, https://cordis.europa.eu/

Finally, we highlight how the RD‐Connect GPAP has been
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successfully used in a number of European projects resulting in the

described in Laurie et al. (2016), with only minor variations in the

diagnosis of hundreds of RD cases.

protocol associated to the experimental methodology used in order
to minimize batch effects. The current RD‐Connect processing
pipeline uses BWA‐MEM (version 0.7.8; Li, 2013) for alignment to

2

| M E TH O D S

the hs37d5 version of the human genome and GATK HaplotypeCaller
(v3.6) for the detection of single nucleotide variants and short

2.1

| User registration and data submission

insertions and deletions in line with the GATK Best Practices
workflow (Poplin et al., 2018). In addition to short variant identifica-

Access to the RD‐Connect GPAP is free to all noncommercial

tion, all runs of homozygosity in excess of 500kb in length are

members of the RD research community. To become an authorized

identified (Matalonga et al., 2020), and read depth calculated across

user of the RD‐Connect GPAP, Principal Investigators, or equivalent,

the target region of interest to provide a measure of data quality for

must indicate why they wish to access the platform, and sign the RD‐

each individual experiment. Before any changes to the core pipeline

Connect Adherence Agreement and Code of Conduct (available via

being implemented, the output of the updated pipeline is bench-

https://rd‐connect.eu/forms‐and‐guides/). Applications are then for-

marked for validation against the genome sequencing data for the

warded to the RD‐Connect GPAP Data Access Committee which

NA12878 sample from NIST/GIAB following the guidelines of

consists of four leaders in the field of RDs. Upon approval, the

Krusche et al. (2019), before full reanalysis starting with the raw

Principal Investigator may then request access credentials for other

data of all experiments in RD‐Connect using the new pipeline, to

members of their group, each of whom must also agree to the Code

maintain internal consistency.

of Conduct. Additionally, researchers from countries outside the EU

All detected variants which are covered by both a minimum of

may have to sign a Data Transfer Agreement and a Data Access

eight sequencing reads and having a genotype quality determined

Agreement. The whole process is largely based on ethics research

by GATK of at least 20 are uploaded to the GPAP. Nevertheless,

conducted within the RD‐Connect project (Mascalzoni et al., 2016).

the default filter recommendations are set to a minimum coverage

Data submission is undertaken in three steps. First, the user

of 10 reads and a genotype quality of 30 as our benchmarking has

creates a phenotypic record in the bespoke application PhenoStore,

shown that the proportion of false‐positive calls below a read

describing the case and any family members for which genomic data

depth of 10 increased rapidly. Furthermore, it is in the user's

is available. In the second step, the submitter must provide a small

hands to determine the fraction of reads that should support a

amount of essential metadata to allow data processing to be

heterozygote or homozygote alternative variant call, with defaults

undertaken correctly. This metadata describes the type of experi-

of 0.2–0.8 for a heterozygote, and >0.95 for a homozygote. The

ment performed for example, genomic library preparation and

internal allele frequency for all variant positions in RD‐Connect is

sequencing strategy, and to which participant the data belongs.

also calculated and this can be applied as a filter in the same way

These first two steps can either be performed directly within a user‐

as the variant frequencies from gnomAD and the 1000 genomes

friendly graphical user interface or via bulk upload using MS Excel

project. This internal allele frequency is also shown in the results

templates. In the final step, high‐speed transfer of the raw

view allowing easy identification and removal of any common

sequencing data, in standard formats (FASTQ, BAM, or CRAM) is

alignment and variant calling artifacts from the results. Finally,

facilitated via use of an Aspera server, provided by the Spanish

coverage metrics, for example mean/median depth of coverage,

academic and research network RedIris (https://www.rediris.es/).

and proportion of target region of interest covered by 10 or 20

Furthermore, the RD‐Connect GPAP team can broker, upon

reads etc. for each experiment are available in the Data

agreement, the transfer of raw and processed data to the European

Management module, thus providing users with a measure of

Genome‐Phenome Archive (EGA, Lappalainen et al., 2015) to make

the overall quality of the data for the experiments undergoing

them available to the broader research community. Upon request,

analysis.

data submitted to the RD‐Connect GPAP may be placed under
embargo for up to 6 months, during which time only members of the
submitting group have access to the data. Following expiry of the

2.3 |

RD‐Connect GPAP architecture

embargo period, the genomic data and limited phenotypic data
become visible to all platform users.

The RD‐Connect GPAP variant storage and processing system have
been built on fully scalable technologies. gVCF files output by the
analysis pipeline are stored on a Hadoop File System (https://hadoop.

2.2

| Genomic data processing

apache.org/docs/r1.2.1/hdfs_user_guide.html) and the extract, transform and load process is leveraged by Apache Spark (https://spark.

Submitted raw sequencing data is processed through a benchmarked

apache.org/) and Hail (https://hail.is/). The output of this process

standard analysis pipeline optimized for the processing of short‐read

is loaded into an Elasticsearch cluster (https://www.elastic.co/

data produced by Illumina and MGI platforms, which is currently the

elasticsearch/) which offers low‐latency response time to user

only type of raw genomic data the platform accepts, largely as

queries.
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RESULTS

distinct modules: Data Management, PhenoStore, and Data
Analysis, each of which consists of a server and client, all being

3.1 |

RD‐Connect GPAP implementation

connected to the same Identity Provider (Keycloak, https://www.
keycloak.org/). The PhenoStore server is implemented in Python/

From the user's perspective the RD‐Connect GPAP consists of 3 core

Flask (https://flask.palletsprojects.com/), the Data Analysis server

modules (Figure 1):

in Scala/Play2 (https://www.playframework.com/), and the Data
Management module written in Python/Django (https://www.

(1) The Data Management module, which facilitates the upload of

djangoproject.com/). The clients are all single‐page application

raw sequencing data, together with associated metadata required

implementations written in JavaScript and React (https://reactjs.

for processing.

org/). In addition to these core modules, other microservice

(2) PhenoStore, an application for the storage and sharing of

modules have been developed such as the MME and Beacon V1

phenotypic descriptions of all participants (affected individuals

(Fiume et al., 2019) servers.

and relatives), which uses machine readable ontologies and

The RD‐Connect GPAP is hosted by the data centre of the

vocabularies such as HPO, ORDO, and OMIM.

Centro Nacional de Análisis Genómico (CNAG‐CRG, Barcelona,

(3) The Genomic Analysis module, where researchers/clinicians

Spain). For security purposes, the Unix cluster nodes are not

analyze their own cases, and can discover and access data from

connected to the internet and only communicate to the outside

cases shared by other researchers, to identify disease‐causing

world via a controlled proxy server. The platform stands behind a

variants.

firewall which permits outbound requests from the internal nodes
only if the host destination is on a white list, meanwhile inbound
requests are all validated by a reverse proxy which then derives the

3.1.1 |

Data management

request to the relevant service. The server and client libraries are
continuously updated to the latest versions to minimize security

The Data Management module facilitates the upload of sequencing

vulnerabilities, and platform security is audited periodically by an

data and metadata and allows users to keep track of all data they

external company to test for vulnerabilities: firstly, black box testing

have submitted. With this module, they can easily check for how

against the platform APIs is undertaken, and secondly, a security

many participants they have entered data into the system, which

engineer is given standard user credentials and they attempt to

types of experiments are linked to these participants, which

upscale their permissions to gain access to information for which they

associated files were uploaded, and to which projects they pertain

do not have credentials (gray box testing). Any minor vulnerabilities

(Supp. Figure S1). They can also track the progress of their

identified are then immediately patched.

submission, data processing, and analysis status. Further, submitters
can see which RD‐Connect GPAP users have made queries
specifically on their genomic datasets.

2.4

| Data standards

To enable interoperability and to overcome language barriers, the

3.1.2 |

PhenoStore

RD‐Connect GPAP has been designed to use widely adopted and
machine readable international and community standards and

A requirement for collaboration in the RD‐Connect GPAP is that all

ontologies whenever possible. Within the PhenoStore module,

submitted genomic data be accompanied by a corresponding

patient descriptions are recorded using HPO, ORPHA, and OMIM

pseudonymised phenotypic description of the individual from whom

(Amberger et al., 2015) terminology. Phenotypic records can be

the sample was taken, which is recorded within the PhenoStore

exported to the GA4GH approved Phenopackets file format (https://

module developed primarily within the EJP‐RD. A deep phenotypic

github.com/phenopackets/phenopacket‐schema), and family trees in

record for affected individuals can be generated using HPO terms,

PLINK PED format (Purcell et al., 2007). Genomic alignments and

which describe observed patient signs and symptoms and, when

variants are stored and transferred (e.g. to the EGA) in GA4GH

informative, the absence of certain traits. HPO is a machine‐readable

approved

respectively

standardized vocabulary which aids in breaking language barriers,

(https://www.ga4gh.org/genomic‐data‐toolkit/). Biological annota-

since each of the terms consists of a unique code linked to a

tions, available in the Data Analysis module are provided by Ensembl

description and additional information (e.g., synonyms, comments)

Variant Effect Predictor (McLaren et al., 2016), and supplemented

which have been translated into several languages. HPO is

with data from other human genomics community resources such

continuously being updated, and new terms are added as necessary,

BAM/CRAM,

and

gVCF/VCF

formats,

as ClinVar, gnomAD (Karczewski et al., 2020), and PanelApp.

and one of the successful mechanisms to update HPO, and broaden

Data discovery and sharing are facilitated through the implementa-

its usage, were workshops organized with disease experts from

tion of GA4GH Beacon V1 and MME APIs.

RD‐connect and Solve‐RD, among others (Kohler et al., 2021). Where

LAURIE

|

ET AL.

723

F I G U R E 1 Flow of genome‐phenome data in the RD‐Connect Genome‐Phenome Analysis Platform. Clinical scientists submit their data to
the RD‐Connect GPAP wherein it is processed through a standard analysis pipeline. The variants identified are returned to the user via a
user‐friendly interface where they can undertake filtration and prioritization to diagnose their rare disease cases. This effort is supported by the
integration of data from a large variety of external resources, and through live links via APIs to other resources. When an inconclusive but
interesting result is found, patient matchmaking may be performed using the Matchmaker Exchange API to query other similar resources around
the world

the RD diagnosis is known at the time of submission, or upon

sources such as HPO, OMIM, DisGeNET (Piñero et al., 2020), and

case resolution, an ORPHA and/or OMIM identifier can be added to

Exomiser (Smedley et al., 2015). Similarly, machine‐readable pheno-

the record, together with a description of the causative variant(s).

typic descriptions are essential for patient matchmaking both within

Each individual record is assigned to a specific family within the

the RD‐Connect GPAP and worldwide via the MME network.

system, and a user‐friendly pedigree‐drawing tool facilitates the

Furthermore, data stored in PhenoStore can be exported to

linking and addition of family members.

Phenopackets, a GA4GH open file standard for interoperability,

For projects focussing on a particular class of RD, customized

transfer, and sharing of disease and phenotypic information. The

templates are available in PhenoStore to accelerate data collation. In

RD‐Connect GPAP was one of the first testers and early adopters of

collaboration with Orphanet and members from several European

Phenopackets, which are now extensively used within the Solve‐RD

Reference Networks (https://ec.europa.eu/health/ern_en), 20 tem-

project as part of its data sharing and analysis strategy (manuscript in

plates based on the Genomics England RD data model (https://www.

preparation).

genomicsengland.co.uk/?wpdmdl=5500) have been implemented.
These templates, which include diseases from all 24 European
Reference Networks, promote data standardization and harmoniza-

3.1.3 |

Genomic analysis module

tion, by indicating which fields and HPO terms are most likely to be
relevant for the appropriate RD class, though all HPOs remain

The Genomic Analysis module is the analytical core of the

available for selection. The templates may also include measurements

RD‐Connect GPAP, where researchers and clinicians analyze their

that are not currently defined within the HPO, for example, the

own RD cases through the integration of the phenotypic information

number of observed polyps in the case of tumor risk syndromes, or

they have supplied, and the application of filters based on multiple

measurements of key molecular biomarkers. Together these provide

annotations, tools and resources built into, or accessible from, the

a deep and meaningful description of the case which is easily

platform. The primary use case for the analysis is to discover disease‐

understood by both human and machine alike. The latter is invaluable

causing variants in a submitted index case or family structure, and the

because it means that the phenotypic description can be directly

system supports variant analysis in both a “diagnostic” paradigm

applied by the user when undertaking variant prioritization within the

(known variants or variants in known genes) and a “discovery”

Genomic Analysis module via the generation of real‐time in silico

paradigm (potentially damaging variants in genes not previously

candidate gene panels through the integration of information from

associated with disease).
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To begin an analysis, the user selects the samples they want to

including time‐stamping, username recording, and the outcome of the

analyze and defines the mode of inheritance they wish to investigate.

analysis (e.g., solved case, negative case, variant under segregation

Following this, a range of filters can be applied within four broad

analysis etc.). This information is accessible through the different RD‐

categories: variant effect (McLaren et al., 2016) including presence in

Connect GPAP modules, facilitating case follow‐up and reporting.

ClinVar; allele frequency described in control populations such as

Where initial analyses do not turn up any interesting variants from

gnomAD and the 1000 Genomes Project (Genomes Project et al.,

disease genes known to be associated with the phenotype of the case

2015); predicted variant impact as determined by popular machine‐

being investigated, the user may then shift to a gene discovery

learning algorithms such as PolyPhen (Adzhubei et al., 2013) and

approach through more detailed investigation of variants that have

CADD (Kircher et al., 2014); application of customized candidate gene

passed the applied filters but are in unfamiliar genes. There are a

lists, (see Table S1 for a detailed list of filtering options, and

number of features within the platform that facilitate this extended

Figures S2 and S3 for screenshots). The user can add or remove

investigation. The simplest of these is the extended results view which

filtering terms at will, and rerun their query, which will return updated

indicates if genes are known to be involved in certain pathways,

results in seconds.

regulatory networks, or implicated in disease through annotations

Summary results are displayed with color‐coding to highlight

provided by databases such as Wikipathways, Reactome, and

variants likely to be of particular interest, for example, variants

DisGeNet, and so on (see Table S2). A more advanced feature is the

recorded to be Likely Pathogenic or Pathogenic in ClinVar, and/or

search‐across‐all tool which allows a user to search across all shared

those predicted to be damaging by machine‐learning trained tools. To

samples, or a user‐defined sub‐cohort of samples, to see if a particular

ease further exploration of variants of interest, hyperlinks to the

variant, or a similar type of variant in the same gene is found in other

appropriate record in popular genomic web servers are provided at

affected individuals in the RD‐Connect GPAP, for example, a HIGH

both co‐ordinate and gene level for example, OMIM, Ensembl (Howe

impact homozygous alternative variant in gene X. If such variants are

et al., 2021), gnomAD, the Human Gene Mutation database (Stenson

commonly found in other cases, this would imply that the initial variant

et al., 2020), and the University of California at Santa Cruz Genome

is less likely to be clinically relevant. However, if such variants are

Browser (Kent et al., 2002). A full list of resources used in the

rarely found, but there is another case in the platform which has a

platform is provided in Table S2.

somewhat similar phenotypic description, then this may suggest that

Furthermore, the RD‐Connect GPAP provides fully detailed

the variant is worth pursuing further as it may represent a case of

annotations for each variant in an extended results section, including

phenotypic expansion, or may indicate that one or other of the

the functional effect of the variant at the level of each Ensembl

phenotypic descriptions is incomplete. When a good candidate is

transcript, variant quality metrics, protein pathway, and interaction

found in the latter case, the user has access to a contact button that

data, amongst others.

sends a mail to the submitter of the newly identified case to initiate
contact with both the user and the owner receiving a mail, as does the
RD‐Connect helpdesk, allowing the researchers to compare notes and

3.1.4

| Advanced features

follow‐up at their own discretion. If the search‐across‐all proves
fruitless, but a novel variant still appear highly interesting, then internal

In addition to the more standard features described above, the

(within RD‐Connect) and external matchmaking is possible allowing

RD‐Connect GPAP uniquely brings together information from a wide

the user to look for other cases, around the world, which have a similar

variety of sources which facilitate variant filtration, prioritization, and

phenotype and variants in the same gene (see Implementation of

interpretation, beyond that provided by simple biological annotation.

Matchmaker Exchange API section below).

These include the ability to generate candidate gene lists on‐the‐fly via
API connections to resources such as PanelApp, HPO, and DisGeNET.
Long runs of homozygosity (>500kb) are identified in all experiments,
and can be used as a filter within the platform, which is particularly

3.1.5 | Demonstration instance, training, and
feedback

useful when attempting to resolve cases in consanguineous progeny
(Matalonga et al., 2020). Exomiser can be used to rank a shortlist of

To provide potential new collaborators with the opportunity to test

candidate variants using the HPO terms in the corresponding

the system, and to facilitate training and workshops, a demonstration

PhenoStore record, thus providing an accurate indication as to

instance of the platform is available (https://playground.rd‐connect.

whether any variant is likely to be causal. Furthermore, hyperlinks to

eu/), which includes virtually all of the functionality available within the

the appropriate page in resources which provide more detailed

Genomic Analysis and PhenoStore modules. The genomic data therein

information for specific variants are provided, such as Varsome

comprises several trios based upon Illumina Platinum genome

(Kopanos et al., 2019) for classification according to ACMG criteria.

sequencing of the best‐characterized human genome in the world,

In combination, these features expedite the task of determining

the HapMap sample NA12878/HG001 and her parents, NA12891 and

whether any variants returned by the initial filtering strategy are likely

NA12892 (Eberle et al., 2017). The sequencing data were processed

to be explanatory for the case under examination (Table 1). Tracking of

using the same analysis pipeline as for any other submitted sample but,

the status of ongoing analysis of specific cases is also enabled,

before uploading the variants, causative variants from real cases were
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Advanced features in the RD‐Connect Genome‐Phenome Analysis Platform for variant filtration, prioritization and interpretation

Objective

Method

Tools/Resources

Variant filtration

Generate candidate gene lists on‐the‐fly
via APIs

•
•
•
•
•

Variant filtration

Identify variants in long runs of
homozygosity

Runs of homozygosity >500 kb, 1 Mb, and 2 Mb in length are identified as
described in Kancheva et al. (2016)

Variant filtration

Remove common variants

Filter by allele frequency from:
• RD‐Connect Internal Frequency
• gnomAD (Karczewski et al., 2020)
• 1000 Genomes Project (Genomes Project et al., 2015)

Variant prioritization

Score and rank list of candidate variants
according to supplied HPO terms

• Exomiser (Smedley et al., 2015)

Variant Iinterpretation

Hyperlinks to appropriate records in
external resources

•
•
•
•
•

Variant interpretation

Classify according to ACMG Criteria

Link from variant to Varsome (Kopanos et al., 2019)

Search for variant in patient cohort

This internal search tool allows querying for specific genes or variants of
interest across a cohort of accessible samples in the platform

Tagging Variants

Users can tag variants in the platform and attribute a clinical significance, in
accordance with the ACMG guidelines, for a specific patient and disorder.
These tagged variants are visible to all other users and may be relevant for
interpretation of their cases.

Internal data discovery

• Search within RD‐Connect GPAP cohorts
• Search across all RD‐Connect GPAP participants
• Internal matchmaking

External data discovery

• Matchmaker Exchange API (Buske et al., 2015)
• Beacon v1 API (Fiume et al., 2019)

Gene discovery

PanelApp (Martin et al., 2019)
Reactome (Fabregat et al., 2018)
HPO (Kohler et al., 2021)
DisGeNET (Piñero et al., 2020)
OMIM (Amberger et al., 2015)

HGMD (Stenson et al., 2020)
ClinVar (Landrum et al., 2020)
VarSeak (www.varseak.bio)
DisGeNET (Piñero et al., 2020)
HmtDB (Clima et al., 2017)

spiked into the gVCFs before upload to generate a variety of simulated

inherently sensitive in nature, and hence must be securely stored,

RD trios. These are paired with corresponding simulated PhenoStore

and access controlled, in accordance with the consented use.

records with relevant HPO terms, allowing testers to attempt to

Furthermore, all data sharing must be in compliance with the

diagnose these cases in the demo instance, as if they were their own

EU General Data Protection Regulation (GDPR, European Parliament

RD cases. The demo instance has proven to be very useful for hands‐

and Council of European Union (2016) Regulation (EU) 2016/

on training on the system itself and also for the human genomics

679; https://eur‐lex.europa.eu/legal‐content/EN/TXT/HTML/?uri=

community, as it has been used by thousands of attendees in over 30

CELEX:32016R0679&from=EN), for which the RD‐Connect GPAP

events including students, researchers, healthcare providers and

is regarded as a data controller.

patients. We have recorded a number of the live webinars we have

To gain access to the RD‐Connect GPAP, interested parties must

given, and furthermore have provided video tutorials on specific types

complete the registration form accessible via the platform home page

of analyses that can be undertaken in the platform, all of which are

(https://platform.rd‐connect.eu/), any queries regarding eligibility can

available via the RD‐Connect YouTube channel (https://www.youtube.

be directed to the helpdesk (help@rd‐connect.eu). For users who do

com/channel/UCwwcUPJZfyWGaW13Lvao7Ag).

not wish to register, variant data can be queried in a limited fashion
via the Beacon Network (https://beacon‐network.org/) thanks to the
implementation of the GA4GH Beacon API. Newer versions of the

3.2 | Data sharing and collaboration in the
RD‐Connect GPAP

Beacon API expected to be available in the near future may allow
queries related to phenotypes and other clinical features. The variant
and phenotypic data for all participants for whom matchmaking

An overarching goal of the RD‐Connect GPAP is to facilitate data

consent has been provided can be queried via partner APIs within the

sharing to promote rapid diagnosis. However, patient data is

Matchmaker Exchange network.
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The RD‐Connect GPAP is designed to facilitate data sharing and

component and a phenotypic component, each of which range

foster collaboration between RD researchers across the world in a

between 0 and 0.5. To compute the genomic score, the genes

number of ways:

from the query are compared with genes that have variants
tagged in the system as “Pathogenic,” “Likely Pathogenic” or

1) Query parameters can be saved through the generation of unique

“Uncertain Significance.” If there is a match of at least one gene,

URLs, thus allowing users to return to their analyses at any point

the genomic score is set to 0.5, otherwise it is set to 0. For the

in the future, and share results easily with other authorized users

phenotypic score, the HPO terms from the request are used to

in the system.

compute similarity with matchable participants from the RD‐

2) Variants of interest can be tagged and user interpretation applied,

Connect GPAP using the UI similarity algorithm (Guo et al., 2006),

which is then visible to all other users. Furthermore, when a user

which is divided by 2 to yield a score between 0 and 0.5. If the

confirms a variant as disease causing within the platform, a similar

sum of the genomic and phenotypic components is greater than

set of information to that required by ClinVar is requested to

0.2, the participant PhenoStore ID is returned in the response to

provide the necessary context and evidence.

the querying node together with the score, the corresponding

3) The search‐across‐all feature allows users who have identified a

HPOs, the matched gene when appropriate, and an internal RD‐

variant of interest in a certain gene to search across all genomic

Connect GPAP email address so that the querying researcher may

datasets available to them within the RD‐Connect GPAP to

initiate contact if deemed relevant.

attempt to discover participants with similar or identical variants.

RD‐Connect GPAP users may only initiate matchmaking requests

If they identify such a variant, a contact button allows them to

for samples which have been submitted by their group and which

contact the submitter of the relevant participants to discuss the

have been cleared for participation in MME. If matchmaking has been

candidate variants further.

permitted, a button with the MME logo is visible in the Data Analysis

4) A combinatorial query on the participants’ information (ORPHA and/

module (see Figure S2). Upon clicking on the MME button a form is

or HPO terms, and assigned European Reference Network) allows

displayed which is automatically filled with the relevant information

definition of in‐silico cohorts of experiments to which the search‐

from the Genomic Analysis module and PhenoStore, including the

across‐all feature can be applied to focus the query more clearly.

HPOs from the participant and any genes for which a variant has

5) The RD‐Connect GPAP is included in the Beacon Network

been tagged. The user must specify to which MME node they wish to

(https://beacon‐network.org/) via the implementation of the

make a request, and may add other HPOs and genes if desired before

GA4GH Beacon API v1, which permits queries to determine if a

sending the request. If the receiving node returns matching results,

particular variant is found in at least one of the experiments in the

the user is presented with a list of matches which may include HPOs,

RD‐Connect GPAP. Likewise, any interesting variant found in the

a gene, or both, depending upon which node is returning a match, and

RD‐Connect GPAP can be immediately queried in other beacons

a button to contact the data custodian of the potential match by

through the Beacon Network.

email.
As further follow‐up is in the hands of the clinical researchers
involved, we are often unaware as to whether a match was

3.2.1 | Implementation of matchmaker
exchange API

conclusive in providing a diagnosis for one or both cases involved,
or whether the cases were found to be too dissimilar upon further
investigation. Nevertheless, we are aware of a number of recent

The MME API (Buske et al., 2015) has been implemented in the RD‐

success stories. For example, matchmaking involving samples from

Connect GPAP for internal and external matchmaking. Internal usage

the Consequitur project has led to the identification of 11 novel

allows matchmaking only between data sets within the platform,

candidate genes in a variety of rare neurological cases presenting

empowering users to identify similar cases both in terms of

with a range of phenotypes including brain malformation, intellectual

phenotype and the variants they carry, thus facilitating confirmation

disability with epilepsy, Charcot‐Marie Tooth syndrome, myopathy,

of causality and case resolution. External usage currently permits

and ataxia (Kurul et al., 2021; Richard et al., 2021). While the

bidirectional communication with four MME nodes: PhenomeCentral

Consequitur cases were Turkish in origin, the cases matched included

(Osmond et al, 2022), Decipher (Foreman et al., 2022), GeneMatcher

individuals living in the UK and Egypt. We are also aware of

(Hamosh et al., 2022), and MyGene2 (https://mygene2.org/

successful matchmaking involving cases living as far apart as Australia

MyGene2/).

and Holland, and a number of matches between Italy, Spain, and

In order for a case in the RD‐Connect GPAP to be

the UK.

discoverable through the MME API, the submitting clinical
researcher must actively provide permission. There are currently
5,736 cases available for matchmaking within the system, with

3.3 |

Impact on rare disease diagnosis

821 unique genes tagged. When a query is received by the RD‐
Connect GPAP node, matches are sought and a score between 0

Since its initial release in 2015, the RD‐Connect GPAP has been

and 1 is calculated. The score consists of the sum of a genomic

involved in the primary analysis and reanalysis of thousands of RD
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cases. Unfortunately, it is not possible to provide an accurate count

majority of identified causative variants being found within long runs

of how many cases have been solved since the successful resolution

of homozygosity as expected, and further strong candidate variants

of cases is not always updated in the system or communicated by the

are still undergoing follow‐up (Kurul et al., 2021).

submitter. The total number of shared genome‐phenome datasets

One of the principal goals of the EU Horizon 2020 Solve‐RD

has grown steadily and now stands at over 22,000, including affected

project is to diagnose RD cases which have previously undergone

participants and relatives. Currently, the total number of affected

exome sequencing and analysis, but remain unsolved, through

participants is 13,676, of which 5,736 are discoverable through

systematic and extended reanalyses and, where resolution remains

MME. The majority of submitted datasets have come from large

inconclusive, extending analyses to beyond the exome approaches,

European consortia projects, but in some cases, data from just a few

including short and long‐read genome sequencing, transcriptomics,

sequenced individuals or trios from independent research groups

metabolomics and so on. To this end, 19,000 genome‐phenome

have been uploaded and cases solved (e.g., Oktay et al., 2020; Owen

datasets are in the process of being collected, processed, and

et al., 2018; Permanyer et al., 2020; Topf et al., 2020; Yaramis et al.,

analyzed in the RD‐Connect GPAP. Programmatic reanalysis of the

2020). Before the initiation of the Solve‐RD project, the three largest

first ~4,000 families resulted in rapid resolution of 120 families (de

projects which had used the system for primary analysis were

Boer et al., 2021; Matalonga et al., 2021; Schüle et al., 2021; te Paske

NeurOmics (https://cordis.europa.eu/project/id/305121/reporting,

et al., 2021; Topf et al., 2021). These numbers, which have increased

n = 1,117 data sets), the Biobanking and Biomolecular Research

substantially since publication, were achieved through the identifica-

Infrastructure—Large Prospective Cohorts (BBMRI‐LPC, https://

tion of causative variants that had either been missed by the original

cordis.europa.eu/project/id/313010/reporting)

sequencing

variant filtering strategies undertaken by submitting centers, or were

project (n = 757), and the Consequitur project (n = 626, Kurul et al.,

exome

dismissed as being unimportant at the time due to a lack of

2021). Currently, the Solve‐RD project is using the RD‐Connect

supporting evidence, but for which further information has come to

GPAP as a key resource for the collection and reanalysis of 19,000

light linking the gene to the phenotype of the case in the intervening

previously unsolved genome‐phenome datasets (Zurek et al., 2021).

period. It is anticipated that further cases from this cohort will be

In addition, the RD‐Connect GPAP is further developed and made

resolved through regular repetition of this automated process once

available to all European researchers through the EJP‐RD Virtual

further new gene‐disease relationships are established by the RD

Platform, and also as an ELIXIR‐ES resource.

community. The RD‐Connect GPAP is interoperable with the rest of

The EU FP7 NeurOmics project, funded in parallel to RD‐

the Solve‐RD data infrastructure, which includes additional compo-

Connect, focussed on the investigation of cases of rare neuro-

nents for data discovery, sharing, and analysis. Of note, all

muscular and neurodegenerative diseases, and was the first large

developments of general use which are triggered by the Solve‐RD

project to upload genome‐phenome data to the RD‐Connect GPAP

project become available to all other RD‐Connect GPAP users.

and use it as one of their analysis tools. This consisted of a total of
671 exome sequencing datasets, and 446 genome sequencing
datasets, from a total of 375 families. By the end of the project in

4 |

D IS CU SS IO N

December 2017, 104 families (28%) had been solved, and over 100
new gene‐disease relationships described (Lochmüller et al., 2018).

The RD‐Connect GPAP has been facilitating collaborative analysis of

The BBMRI‐LPC WES project was an open call offering exome

genome‐phenome data since 2015 by enabling data discovery and

sequencing for transnational European projects with the objective of

sharing, with the aim of accelerating diagnosis and novel gene

diagnosing RD cases and enriching RD sample biobanks. Seventeen

discovery. This has been possible thanks to collaboration within large

projects were selected focussing on different classes of RD for

EU funded projects and international initiatives, which have both

example, rare eye diseases, epileptic encephalopathies, mitochondrial

fueled the development of the system and have shared thousands of

disease, disorders of glycosylation. A total of 757 samples from

datasets, but the platform is also used by many smaller research

379 families were analyzed using the RD‐Connect GPAP, with in‐

groups, such as those based in hospitals. Currently, the platform has

depth analysis undertaken by an in‐house clinical genomics expert

695 active users from 348 research groups across 185 different

and/or external domain experts, with variants of interest returned to

institutions located in 36 countries.

the submitters for follow‐up and confirmation. To date 117 of 273

The powerful range of functionalities provided by the system,

(43%) fully analyzed families have been solved (Ivanovski et al., 2020;

the sharing of data, and the expertize of registered peers, allow

Maini et al., 2018, 2021; Saredi et al., 2019; Urreizti et al., 2020).

clinical researchers to enhance their analyses and/or to give a second

The Consequitur project focussed on progeny from consanguin-

chance to data for which previous analyses were inconclusive. In

eous marriages who have a RD. 626 samples from 190 families were

some cases, a good candidate variant has been found by the

analyzed using the RD‐Connect GPAP. Here the implementation of

submitter shortly after commencing analysis. In other cases, the

an algorithm to detect runs of homozygosity was particularly valuable

diagnosis has been achieved through patient matchmaking either

as most causative variants in such families are likely to be found in

within the platform or with other nodes from MME. In the latter

regions identical by descent (Matalonga et al., 2020). To date,

cases, the patients are typically from different countries, making it

137 families (72%) have been solved using the GPAP, with the

unlikely that the referring clinicians would ever have come into
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contact with one another to discuss their cases were it not for the

programmatic reanalysis mechanisms (Machini et al., 2019; Wright,

matchmaking mechanism.

FitzPatrick, et al., 2018) as has already proven successful in Solve‐RD

To enable data discovery and data sharing, the RD‐Connect

(Matalonga et al., 2021). Finally, to increase the chance of finding

GPAP has addressed many of the barriers that traditionally block

relevant data between resources, the RD‐Connect GPAP is exploring

such activities, beginning with careful and ongoing evaluation of

connections to additional MME nodes and, together with many other

ethical and legal issues, which were initiated during the RD‐Connect

partners, is testing and further developing enhanced mechanisms of

project. This demonstrated that effective genome‐phenome data

data discovery, which may allow more complex queries than those

sharing across countries is possible if the proper procedures and

enabled with the current production versions of the Beacon and

measures are applied. To facilitate data entry and enable inter-

MME APIs. Some of these methods should facilitate the provision of

operability, the platform relies on widely adopted tools and standards

aggregated or summary information to non‐registered users to let

for read alignment, variant detection and annotation, and the

them know, for example, if there is data from individuals with a

recording of phenotype descriptions and diseases. This is particularly

certain disease or phenotype (or even the number of available

relevant within the platform since the phenotypic information

datasets of each kind).

combined with the information from commonly used RD genomics

We are constantly looking for novel methods to aid in RD

resources can be directly applied to the objective of identifying

diagnosis, and with this in mind we are evaluating how other –omics

disease‐causing variants. Taken together with the functionalities that

data (e.g., transcriptomics, proteomics, metabolomics, epigenomics,

address technical barriers by enabling users to analyze data without

etc.) could be incorporated in a systematic and user‐friendly manner

needing their own infrastructure or bioinformatics know‐how, the

to help improve diagnostic yield. Similarly, as long‐read sequencing

RD‐Connect GPAP helps clinicians and researchers to rapidly and

becomes more common, we will also develop workflows to accept

accurately identify which variants are of potential interest. Further-

and process such data. It would also be useful to expand connections

more, the PhenoStore module facilitates data transfer and sharing as

to other types of data source, such as patient registries, biobanks and

records can be easily exported, by individual patient or in bulk, into

biomaterials resources, all of which are included, among others,

Phenopackets, CSV, or PDF formats. The advantage of using

within the EJP‐RD Virtual Platform for RD research of which the

Phenopackets is that the data can then be automatically used or

RD‐Connect GPAP is also a key resource.

imported by tools compliant with this GA4GH standard. As a result,

In summary, the RD‐Connect GPAP has become a key resource

phenotypic and genomics data can be re‐used within the RD‐Connect

in the EU for clinical research and has helped advance the field of

GPAP or beyond if it is shared within a consortium infrastructure,

genome‐phenome data discovery, sharing, and analysis. In the years

and/or submitted to a resource enabling controlled access such as

to come, we expect it to grow and develop further, continuing to

the EGA. The Solve‐RD project provides a good demonstration of

accelerate diagnosis and novel gene discovery and contributing to the

how data can be successfully shared and used within a consortium to

IRDiRC Vision for 2027. In this sense, the most tangible impact of the

undertake further analyses beyond those which are currently

RD‐Connect GPAP so far has been to the hundreds of patients, and

possible within the RD‐Connect GPAP (Zurek et al., 2021).

their families, for whom it has contributed to ending their diagnostic

The RD‐Connect GPAP is undergoing continuous development

odyssey.

thanks to participation in several initiatives, and in response to
feedback from its users. In this sense, surveys are conducted in many
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